ReviewTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2026
Serum Eye Drops: Implementation, Upscaling, and Patient-Centered Care - Insights from a Blood Bank in Western Austria.
Review in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Serum eye drops (SEDs) have emerged as an important therapeutic option for the management of severe ocular surface diseases, particularly in cases refractory to conventional treatments. Despite their proven efficacy, the implementation and expansion of SED therapy in clinical practice present logistical, regulatory, and clinical challenges. Although we started producing SED rather recently in 2018 at the Central Institute for Blood Transfusion and Immunology in Innsbruck, Austria, we were producing more than 750 monthly packages in 2024. We were able to establish a service-oriented workflow for our constantly growing number of patients, also reflecting the urgent need for this therapy. Summary: This review provides an overview of the indications and mechanisms of action of SED, summarizes current evidence for their efficacy and safety, and details the stepwise approach taken to implement and upscale SED therapy at our blood bank. Key aspects include patient selection criteria, preparation, and quality control of autologous and allogeneic SED, interdisciplinary collaboration, and the development of standardized protocols. The article also addresses barriers encountered during implementation, such as regulatory requirements and resource allocation, and outlines solutions adopted to ensure sustainable and patient-centered care. Key Messages: SEDs represent a valuable addition to the therapeutic arsenal for ocular surface disorders, offering significant benefits in selected patient populations. It is therefore important that more blood banks in Europe include SEDs in their product portfolio in the future to meet the increasing demand. However, the successful implementation and upscaling of SED therapy require multidisciplinary collaboration between blood bank, ophthalmologists, pharmacies, and health insurances, as well as excellent logistics infrastructure, to comply with strict regulatory requirements. Standardized protocols, continuously ongoing staff training, and patient education are critical for optimizing clinical outcomes and ensuring the long-term sustainability of SED programs in large medical centers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.